



RESEARCH ARTICLE

On the intrinsic disorder status of the major players in programmed cell death pathways [v1; ref status: indexed, <http://f1000r.es/1me>]

Alexey V Uversky¹, Bin Xue², Zhenling Peng³, Lukasz Kurgan³, Vladimir N Uversky^{2,4,5}

¹Center for Data Analytics and Biomedical Informatics, Department of Computer and Information Sciences, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA

²Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, FL, 33612, USA

³Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada

⁴Byrd Alzheimer's Research Institute, College of Medicine, University of South Florida, Tampa, FL, 33612, USA

⁵Institute for Biological Instrumentation, Russian Academy of Sciences, 142290 Pushchino, Russian Federation

v1 **First Published:** 17 Sep 2013, 2:190 (doi: 10.12688/f1000research.2-190.v1)
Latest Published: 17 Sep 2013, 2:190 (doi: 10.12688/f1000research.2-190.v1)

Abstract

Earlier computational and bioinformatics analysis of several large protein datasets across 28 species showed that proteins involved in regulation and execution of programmed cell death (PCD) possess substantial amounts of intrinsic disorder. Based on the comprehensive analysis of these datasets by a wide array of modern bioinformatics tools it was concluded that disordered regions of PCD-related proteins are involved in a multitude of biological functions and interactions with various partners, possess numerous posttranslational modification sites, and have specific evolutionary patterns (Peng *et al.* 2013). This study extends our previous work by providing information on the intrinsic disorder status of some of the major players of the three major PCD pathways: apoptosis, autophagy, and necroptosis. We also present a detailed description of the disorder status and interactomes of selected proteins that are involved in the p53-mediated apoptotic signaling pathways.

Article Status Summary

Referee Responses

Referees	1	2
v1 published 17 Sep 2013	 report 1	 report 1

1 **Martin Vabulas**, Goethe Universitiy
Frankfurt Germany

2 **Oxana Galzitskaya**, Russian Academy of
Sciences Russian Federation

Latest Comments

No Comments Yet

Corresponding author: Vladimir N Uversky (vuffersky@health.usf.edu)

How to cite this article: Uversky AV, Xue B, Peng Z *et al.* (2013) On the intrinsic disorder status of the major players in programmed cell death pathways [v1; ref status: indexed, <http://f1000r.es/1me>] *F1000Research* 2013, 2:190 (doi: 10.12688/f1000research.2-190.v1)

Copyright: © 2013 Uversky AV *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Grant information: This work was supported in part by University of South Florida (V.N.U. and B.X.), Temple University (A.V.U.), the Programs of the Russian Academy of Sciences for the "Molecular and Cellular Biology" (to V.N.U), the Alberta Innovates Graduate Scholarship in Omics (to Z.P.), and the Natural Sciences and Engineering Research Council (NSERC) Discovery grant (to L.K.).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Authors have no competing interests.

First Published: 17 Sep 2013, 2:190 (doi: 10.12688/f1000research.2-190.v1)

First Indexed: 23 Oct 2013, 2:190 (doi: 10.12688/f1000research.2-190.v1)

Introduction

Many biologically active proteins do not have a unique 3-D structure as a whole or in part¹⁻⁵, and are as such described as intrinsically disordered proteins (IDPs) and hybrid proteins containing ordered domains and IDP regions (IDPRs). These proteins and regions possess highly flexible structures and exist as conformational dynamic ensembles characterized by different degree and depth of disorder^{2,4,6-10}. Globally, the structure of IDPs/IDPRs can be described as collapsed-disordered (molten globule-like), partially collapsed-disordered (pre-molten globule-like), or extended-disordered (coil-like)^{8,11}. IDPs/IDPRs are highly abundant in virtually any given proteome^{1,3,5,12}. As they are abundant constituents of all cells, tissues, and organs, and are responsible for crucial controlling and regulating functions, IDPs are commonly involved in the pathogenesis of various human diseases¹³. This conclusion is based on numerous case studies in which a particular IDP was shown to be associated with a particular disease (including many cancer¹⁴⁻¹⁹ and neurodegeneration-related proteins²⁰⁻²⁷), as well as on the results of systematic bioinformatics studies^{12,28-36}.

The phenomenon of intrinsic disorder in proteins is spreading through modern protein science, and is implemented in more and more aspects of protein functionality. The biological functions of IDPs/IDPRs include involvement in regulation, signaling, and controlling pathways^{29,37,38}. These disorder-based functions represent a crucial complementation to the functional repertoire of ordered proteins^{30,39-41}. Conformational plasticity, pliability, and adjustability combined with functional versatility define the overall natural abundance of IDP/IDPRs. As a result, many (if not the vast majority) of the non-catalytic functions of proteins frequently rely on the advantages provided by the lack of a fixed unique structure^{30,39-41}.

In addition to being crucial for the functionality of many individual proteins, intrinsic disorder plays a vital role in the control of almost all cellular processes. For example, in our recent study, we analyzed the abundance and roles of intrinsic disorder in proteins involved in the various pathways related to programmed cell death (PCD)⁴². PCD represents a suicidal cellular response to the exposure to a set of environmental factors that trigger a chain of specific intracellular biochemical events leading to characteristic morphological cellular changes, and ultimately to cell death.

The three PCD routes (or PCD types I, II and III, which correspond to apoptosis, autophagy, and necroptosis, respectively) have very different biological roles. Apoptosis is important for the development, immune regulation, and homeostasis of a multi-cellular organism. Necroptosis plays a role in the modulation of the inflammatory response in the skin and intestine, serves as a backup mechanism to clear pathogens, and is involved in the immunologically silent maintenance of the T cell homeostasis⁴³. Autophagy controls a wide range of physiological processes such as starvation, cell differentiation, cell survival, and death⁴⁴⁻⁴⁶. It regulates the turnover of long-lived proteins, the disposal of damaged organelles and misfolded proteins, and the turnover of cellular building blocks following nutrient deprivation. As a result, autophagy typically has crucial pro-survival roles in cellular homeostasis and during stress. However, under some circumstances, it can initiate characteristic

cell death^{44,47}. Therefore, although apoptosis and necroptosis both invariably contribute to cell death, autophagy might play either pro-survival or pro-death roles⁴⁷⁻⁴⁹. As a result, the fate of the cells and the fine balance between cell death and survival of healthy cells is jointly decided by the interplay between these three PCD pathways⁴⁹.

Since these three major PCD mechanisms involve different signaling pathways, they can be easily distinguished from each other based on their specific morphological features and on the unique biochemical changes developing in dying cells^{47,50}. Among the characteristic morphological features of the three PCD types are the apoptosis-specific fragmentation and condensation of chromatin, combined with the fragmentation of chromosomal DNA, characteristic fragmentation of nucleus, shrinkage of cells, and production of cell fragments known as apoptotic bodies⁴⁹; the autophagy-linked formation of autophagosomes, which are the double- or multimembrane-bound structures around the recycling-destined cytoplasmic macromolecules and organelles^{49,51-55}; and the necroptosis-related dysfunction of organelles accompanied by the swelling and lysis of cells⁵⁶.

Although a wide range of cell signals of either extracellular or intracellular origin can lead to the activation of various pathways eventually resulting in the initiation of apoptosis, the major cause of the cell death is related to the organized degradation of cellular organelles by activated members of the caspase family of cysteine proteases⁵⁷. Depending on the origin of the triggering signal, apoptotic pathways are classified as extrinsic and intrinsic, and each of these pathways can be regulated at multiple levels. Furthermore, depending on the nature of the cell signals, both apoptotic pathways can be either initiated or repressed. Among the extracellular (or extrinsic) inducers of apoptosis are various cytokines, nitric oxide⁵⁸⁻⁶⁰, hormones, growth factors, and toxins⁶¹, which somehow cross the plasma membrane or transduce to affect a response. Among the major players of the extrinsic apoptosis pathway are cell surface receptors known as death receptors, decoy receptors serving as inhibitory counterparts of these death receptors, are a set of related cytoplasmic proteins⁶². Furthermore, this pathway is regulated by changes in the transcription levels of the death inhibitory proteins (e.g., FLIP) and by the variations in the expression levels of the specific cytoplasmic adapter proteins, such as FADD and other apoptosis-activating ligands, leading to the procaspase activation^{62,63}. Among the intracellular triggers of apoptosis are specific signals released by a damaged cell in response to different types of stress, such as heat, radiation, nutrient deprivation, increased intracellular calcium concentration⁶⁴, hypoxia, or viral infection. The intrinsic pathway centers on the mitochondria that contains several key apoptogenic factors such as cytochrome *c*, AIF, SMAC/DIABLO, Htra2/Omi^{65,66}, and endoG⁶⁷⁻⁶⁹; the release of these factors from mitochondria is regulated by the pro- and anti-death members of the BCL-2 family⁷⁰. Also, members of the inhibitor of apoptosis protein (IAP) family of functionally and structurally related proteins control both intrinsic and extrinsic apoptosis pathways, serving as endogenous apoptosis inhibitors⁶². Finally, a unique regulatory role is played by a transcription factor p53 via its modulation of many key control points in both the extrinsic and intrinsic pathways⁶².

Among the major molecular players of autophagy are the mammalian target of rapamycin kinase (mTOR), the ULK1 kinase complex³², the class III PI(3)-kinase VPS34, Beclin-1³¹, and several members of the ATG family that possess various biological functions⁴⁷. Regulators of necroptosis are specific to cell types being different for the apoptosis-competent and the apoptosis-incompetent cells. In fact, RIP1 kinase and death receptors play a role in activation and control of the necroptosis in the apoptosis-incompetent cells⁷¹, whereas the necroptosis of the apoptosis-competent cells is regulated by reactive oxygen species, apoptosis inducing factor (AIF), death-associated protein kinase (DAPK), and c-Jun N-terminal kinase (JNK)⁷²⁻⁷⁵.

Earlier we reported the results of a comprehensive computational analysis of 1138 human apoptosis-related proteins, 137 human proteins associated with and autophagy, and 35 human necroptosis-related proteins, and also studied 3,458 proteins from DeathBase⁷⁶ (<http://deathbase.org/>) that included proteins from five manually curated species: human, mouse, zebrafish, *D. melanogaster*, and *C. elegans*, and 23 reference species⁴². This previous analysis revealed that proteins involved in the regulation and execution of PCD possess substantial amounts of intrinsic disorder; that disorder has numerous functional roles across and within apoptosis, autophagy, and necroptosis processes; and that IDPRs of the PCD-related proteins are engaged in protein-protein interactions, interactions with other partners including nucleic acids and other ligands, and are also enriched with posttranslational modification sites⁴². In the current study, we extend our previous work and provide information on the intrinsic disorder status of some of the major players of the three major PCD pathways: apoptosis, autophagy, and necroptosis. The extension is related to the more focused consideration of the disorder status of several specific human proteins related to the PCD pathways and consideration of the roles of disorder in functions of these proteins; aspects not covered in the previous article. We also present a detailed description of the disorder status and interactomes of selected proteins that are involved in the p53-mediated apoptotic signaling pathways, which was not covered in the previous article. Finally, we provide analysis of available structural information for human proteins related to the p53-controlled apoptotic pathways.

Methods

Datasets

In this study we extend the previous analysis of the abundance and roles of intrinsic disorder in the control and execution of PCD pathways⁴². We report the results of the focused evaluation of intrinsic disorder in specific sub-sets of human proteins in three major modules of the programmed cell death, namely apoptosis, necroptosis, and autophagy. The analyzed proteins are shown in **Figure 1** which represents an interlinked network of protein-protein interactions related to PCD. We also paid special attention to 29 human proteins related to the p53-mediated apoptotic pathways (see **Figure 2**). All human proteins considered in this study were reviewed entries in the UniProtKB Protein Knowledgebase (<http://www.uniprot.org/uniprot/>), and the corresponding FASTA files were downloaded from UniProt.

Computational characterization of disorder

The intrinsic disorder status in these proteins was evaluated by PONDR FIT (<http://www.disprot.org/pondr-fit.php>)⁷⁷, which is

a meta-predictor that combines six individual predictors: PONDR[®] VLXT⁷⁸, PONDR[®] VSL2⁷⁹, PONDR[®] VL3⁸⁰, FoldIndex⁸¹, IUPred⁸², TopIDP⁸³ and by PONDR[®] VLXT⁷⁸. PONDR FIT is somewhat more accurate than the individual predictors used for its development⁷⁷. We also analyzed the disorder status of human protein related to the p53-mediated apoptosis signaling pathways by PONDR[®] VLXT. The use of PONDR[®] VLXT is determined by the ability of this computational tool to visualize potential functional sites important for molecular recognition, signaling, and regulation. These potential binding sites, which are now recognized as Molecular Recognition Features (MoRFs)^{84,85}, occur as dips on the plot of disorder score, and correspond to segments with an increased propensity towards order that are flanked by disordered regions.

Finding α -helix-forming molecular recognition features (α -MoRFs)

MoRFs are short order-prone motifs flanked by disordered regions that are involved in molecular recognition and are able to undergo disorder-to-order transition during binding to a specific partner. The recognition capability of MoRFs and their ability to undergo induced folding at binding are defined by their specific amino acid biases, since these regions usually have a much higher content of aliphatic and aromatic amino acids than disordered regions in general and therefore are computationally identifiable^{84,85}. We used α -MoRF-Pred and α -MoRF-Pred II tools to find α -helix-forming MoRFs^{84,85}.

ANCHOR analysis

The ANCHOR algorithm represents an alternative approach for finding potential binding sites in IDPs and IDPRs^{86,87} (<http://anchor.enzim.hu/>). At the foundation of this approach and its parental tool, the general disorder predictor IUPred^{82,88}, is the estimation of the pairwise energy. Here, the potential binding sites are found as protein segments that cannot form enough favorable intra-chain interactions to fold on their own, but are likely to gain stabilizing energy via specific interactions with globular protein partners^{86,87}. In line with our earlier studies⁸⁹⁻⁹¹, these potential binding regions are termed here as ANCHOR-indicated binding site (AIBS).

STRING analysis

Finally, we looked at the interactions of the functional analysis of these proteins using the STRING database⁹². The STRING database (<http://string-db.org>), which covers more than 1100 completely sequenced organisms, including *Homo sapiens*, represents the online database resource search tool for the retrieval of interacting genes providing both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹². We used two sets of parameters in this analysis. To show the breadth of the p53-centered interactome, the number of interactors was set to 500 and the STRING confidence level was set to 0.900. In the analysis of other human proteins involved in the p53-controlled apoptotic signaling pathways, the number of interactors was set to 20 and the medium confidence level of 0.4 was used.




Figure 1. Schematic representation of three PCD modules. Diagram shows a map of the regulators and molecular components of the apoptosis, autophagy, and necroptosis pathways, constituting the three known modules of the programmed cell death (PCD) network. The proteins are color coded according to their intrinsic disorder content evaluated by PONDR-FIT, with highly ordered ($[I\Delta P\ score] < 10\%$), moderately disordered ($10\% \leq [I\Delta P\ score] < 30\%$), and highly disordered ($[I\Delta P\ score] \geq 30\%$), and is reproduced from⁴².




Figure 2. Schematic representation of the p53-mediated apoptotic signaling pathways. Diagram shows a map of the regulators and molecular components of this pathway. The proteins are color coded according to their intrinsic disorder content evaluated by PONDR-FIT, with highly ordered ($[IDP\ score] < 10\%$), moderately disordered ($10\% \le [IDP\ score] < 30\%$), and highly disordered ($[IDP\ score] \ge 30\%$) being shown as blue, pink, and red boxes, respectively. This diagram is based on the maps of the p53-mediated apoptotic signaling pathways available at (<http://www.ebioscience.com/resources/pathways/p53-mediated-apoptosis-pathway.htm>) and (<http://www.qiagen.com/Products/Genes and Pathways/Pathway Details/?pwid=338>) and on related information^{62,109,151,152} and many other papers.

Results and discussion

Figure 1 (which is adopted from Peng *et al.*⁴²) schematically represents the interlinked nature of the three PCD-related modules by showing some major events taking place within a cell undergoing apoptosis, autophagy, or necroptosis⁴⁷. Figure 1 clearly shows that the various programmed cell death processes are under tight control and

that the involved proteins are strongly interconnected. In fact, it is clear that inside the challenged cell, there is a common programmed cell death network that integrates three PCD modules, which include many pathways that are intertwined and interconnected, and many death regulatory proteins that are used by more than one module⁴⁷. Our previous study suggested that one of the common structural

features of these PCD-related proteins is their strong propensity for being disordered or to possess long IDPRs⁴². We believe that this disordered nature of PCD-controlling proteins allows them to be uniquely and effectively modulated via multiple specific interaction with various partners effectively, and to control the regulation and execution of different PCD modules⁴².

This conclusion is supported by a simple visualization technique used in **Figure 1**, namely, coding the involved proteins according to their intrinsic disorder content evaluated by PONDR-FIT. We used two arbitrary cutoffs for the levels of intrinsic disorder to classify proteins as highly ordered ($[\text{IDP score}] < 0.1$, blue boxes), moderately disordered ($0.1 \leq [\text{IDP score}] < 0.3$, pink boxes) and highly disordered ($[\text{IDP score}] \geq 0.3$, red boxes)³⁶. According to this classification, only 11 human proteins related to the controlled cell death pathways shown in **Figure 1** are characterized by low disorder scores, whereas the absolute majority of the PCD-related proteins are moderately or highly disordered. **Figure 1** also shows that the highly connected PCD-related proteins (i.e., proteins involved in several functional interactions) are typically more disordered than proteins with a lesser number of interaction partners. Interestingly, **Figure 1** also illustrates that although many of the human PCD-related proteins are enzymes (kinases, ribonucleases, deoxyribonuclease, proteases, protein and ubiquitin ligases, polymerases, oxidoreductase, GTPases, etc.), they possess significant disorder levels. The discussion below provides a very brief overview of some major players in three PCD modules and their disorder status.

Description of some major players in three PCD modules and their disorder status

The paragraphs below provide a more focused description of some major functions ascribed to the proteins in the three PCD modules shown in **Figure 1**. This description is further enhanced by our analysis of the disorder status of these proteins, where all mean PONDR-FIT scores were determined in this study.

Apoptosis is a type I programmed cell death that is essential for the elimination of unwanted cells during normal development, and for the maintenance of tissue homeostasis. Apoptosis starts with the formation of multiprotein complexes. One of these complexes is the extrinsic pathway-specific death-inducing signaling complex (DISC) triggered by binding of extracellular death ligands to death receptors. Typical DISC consists of the death receptor FAS (mean PONDR FIT score of 0.281), death ligand (mean PONDR FIT score of 0.394), adaptor proteins such as FADD (mean PONDR FIT score of 0.274) and TRADD (mean PONDR FIT score of 0.298)⁹³. Another important complex formed at these early apoptosis stages is the intrinsic pathway-specific apoptosome, consisting of APAF1 (mean PONDR FIT score of 0.154) and cytochrome *c* (mean PONDR FIT score of 0.327), formation of which is triggered by the cytochrome *c* release from the mitochondria^{94,95}. At the next stage, initiator caspases (such as caspase-2 (mean PONDR FIT score of 0.122), caspase-8 (mean PONDR FIT score of 0.178), and caspase-9 (mean PONDR FIT score of 0.271)) are recruited and activated by these initial complexes. These secondary complexes then cleave and activate effector caspases, including caspase-3 (mean PONDR FIT score of 0.303) and caspase-7 (mean PONDR FIT score of 0.221), that target specific cellular substrates for proteolysis⁵⁷. Caspases are

directly inhibited by members of the IAP family (such as HIAP1 (mean PONDR FIT score of 0.212), HIAP2 (mean PONDR FIT score of 0.215), XIAP (mean PONDR FIT score of 0.177)), as well as by Bruce (mean PONDR FIT score of 0.223) and Survivin (mean PONDR FIT score of 0.373). Anti-apoptotic and pro-apoptotic members of the BCL-2 family (such as BCL-x_L (mean PONDR FIT score of 0.330), BCL-2 (mean PONDR FIT score of 0.347), and BCL-W (mean PONDR FIT score of 0.093)) regulate the release of apoptogenic factors from the mitochondria, including cytochrome *c* and an IAP inhibitor SMAC (mean PONDR FIT score of 0.234)^{94,95}. Caspase-8 mediated cleavage of BID (mean PONDR FIT score of 0.374), a BH3-only member of the BCL-2 family, links the extrinsic and intrinsic pathways⁹⁶.

Autophagy is induced via the suppression of mTOR (mean PONDR FIT score of 0.089), a sensor of growth factors and nutrient availability, leading to the release of its inhibitory effects on the ULK1 kinase complex (mean PONDR FIT score of 0.546)³². Membrane nucleation requires the class III PI(3)-kinase VPS34 (mean PONDR FIT score of 0.209) and its associated proteins, including Beclin-1 (mean PONDR FIT score of 0.400)³¹. Two ubiquitin-like conjugation schemes (the ATG5–ATG12 (mean PONDR FIT scores of 0.091 and 0.464, respectively) and LC3-phosphatidylethanolamine (PE) systems (mean PONDR FIT score of 0.306)) mediate the elongation of the autophagosome membrane. At the molecular level, autophagy is mediated by several members of the ATG family that possess various biological functions⁴⁷. For example, ATG1 (mean PONDR FIT score of 0.546) is a serine/threonine-protein kinase that acts upstream of phosphatidylinositol 3-kinase PIK3C3 to regulate the formation of autophagosomes, the precursors of autophagosomes. ATG10 (mean PONDR FIT score of 0.114) and ATG3 (mean PONDR FIT score of 0.452) act as E2-like enzymes responsible for conjugation of ubiquitin-like ATG12 (mean PONDR FIT score of 0.464) to ATG5 (mean PONDR FIT score of 0.091) and ATG8-like proteins (mean PONDR FIT score of 0.306) to PE, respectively, whereas ATG7 (mean PONDR FIT score of 0.064) serves as an E1-like enzyme that facilitates the reaction of conjugation of ATG8-like proteins to PE by forming an E1-E2 complex with ATG3.

Finally, a few words about the major players in necroptosis are given below. One of the better understood necroptosis models is where this pathway is initiated by the ligand-bound tumor necrosis factor receptor 1 (TNFR1) trimers (mean PONDR FIT score of 0.167)⁴⁸, which recruit multiple proteins such as TNFR-associated death domain (TRADD, mean PONDR FIT score of 0.298), receptor-interacting protein kinase 1 (RIPK1, better known as RIP1, mean PONDR FIT score of 0.276), TRAF2 (mean PONDR FIT score of 0.036), and TRAF5 (mean PONDR FIT score of 0.079). Polyubiquitination of RIP1 triggers the canonical pathway of activation of the transcription factor NF- κ B (mean PONDR FIT score of 0.202) which conveys protection against cell death⁹⁷. However, TNFR1 internalization and RIP1 deubiquitination may lead to the formation of the DISC complex that includes RIP1 (mean PONDR FIT score of 0.276), receptor interacting protein kinase 3 (RIPK3, better known as RIP3, mean PONDR FIT score of 0.431), TRADD (mean PONDR FIT score of 0.298), FAS-associated protein with a death domain (FADD, mean PONDR FIT score of 0.274), and caspase-8 (mean PONDR FIT score of 0.178), which, when activated

by the DISC complex, typically initiates apoptosis⁴⁸. Caspase-8 can be activated not only by TNFR1, but also by other death receptors (such as FAS (mean PONDR FIT score of 0.281)⁹⁸, TNF-related apoptosis-inducing ligand receptors 1 and 2 (TRAIL-R1, mean PONDR FIT score of 0.323 and TRAIL R2, mean PONDR FIT score of 0.495)⁴⁸), ultimately leading to the initiation of apoptosis. However, when caspase-8 cannot be activated (i.e., when it is inhibited or depleted), the cell undergoes necroptosis, which is induced by the formation of a necrosis-inducing complex, necrosome, comprised of RIP1 and RIP3⁹⁹. This RIP1-RIP3 necrosome generates several pronecrotic signals, including activation of c-JUN N-terminal kinases 1 and 2 (JNK1, mean PONDR FIT score of 0.155, and JNK2, mean PONDR FIT score of 0.184) that eventually mediates a signaling cascade affecting the iron storage compartment^{99,100}. Another necroptosis activating pathway is related to the overactivation of poly-ADP-ribose polymerase 1 (PARP1, mean PONDR FIT score of 0.194) leading to the depletion of ATP and NAD, accumulation of poly-ADP-ribose (PAR), and the cytosolic release of apoptosis-inducing factor (AIF, mean PONDR FIT score of 0.162), a protein that is normally secured within the mitochondrial intermembrane space, but upon release from the mitochondria rapidly translocates to the nucleus where it initiates large-scale, caspase-independent DNA fragmentation, leading to further PARP1 activation and subsequent cell death⁴⁸. Finally, necroptosis is accompanied by the release of high-mobility group box 1 protein (HMGB1, mean PONDR FIT score of 0.774), which is both a nuclear factor (which serves as an architectural chromatin-binding factor that bends DNA and promotes protein assembly on specific DNA targets) and a secreted protein serving as a potent mediator of inflammation¹⁰¹. This HMGB1 release is a diffusible signal of necroptosis, which can be used as a cue to nearby cells¹⁰².

Intrinsic disorder of the major regulators of the p53-mediated apoptotic signaling pathways

Figure 2 zooms into the bottom left corner of Figure 1 and shows the p53-mediated apoptotic signaling pathways in more detail. At the center of this signaling pathways is the tumor-related protein p53 (mean PONDR FIT score of 0.519). p53 is a crucial transcription factor, its activation in response to genotoxic or cellular stresses is known to induce or inhibit more than 150 genes^{103,104}. Some of the p53 targets are important players in apoptosis, growth arrest, or senescence pathways^{62,105–107}. Since p53 is an important regulator of various cellular processes (including apoptosis), it has a short lifetime and is normally maintained at low levels in unstressed mammalian cells via continuous ubiquitination and subsequent proteasomal degradation. Normally, ubiquitination of non-phosphorylated p53 is driven by the mouse double minute-2 ubiquitin ligase (Mdm2, mean PONDR FIT score of 0.550), which is capable of targeting p53 for degradation¹⁰⁸. This process is regulated via negative feedback between the p53 and Akt pathways¹⁰⁹. Here, Akt (mean PONDR FIT score of 0.173) is activated in cells exposed to diverse stimuli such as hormones, growth factors, and extracellular matrix components¹¹⁰.

In humans, there is a myriad of growth factors that are able to stimulate cellular growth, proliferation, and cellular differentiation, and some of them can also be involved in apoptosis¹¹¹. Since growth factor proteins typically occur as members of rather large

families of related proteins, the real number of the representatives of this protein class is noticeably larger. For example, there are 23 members in the fibroblast growth factor family (the comprehensive analysis of this very interesting class of proteins is outside the scope of this study). One of the characteristic members of this family of proteins is fibroblast growth factor 1 (FGF1, mean PONDR FIT score of 0.291) that is involved in the regulation of apoptosis. The binding of growth factors to growth factor receptors (e.g., to the fibroblast growth factor receptor 2, FGFR2, mean PONDR FIT score of 0.248) leads to their dimerization and activates their tyrosine kinase activity, causing autophosphorylation of tyrosine residues on the intracellular domain of the receptor. This recruits the p85 regulatory subunit of the phosphoinositol 3-kinase (PI3K p85, mean PONDR FIT score of 0.413) via its SH2 domain, mediating the association of the PI3K p110 catalytic unit (mean PONDR FIT score of 0.164) to the plasma membrane^{109,110}. Activated PI3K phosphorylates membrane-bound PIP2 (phosphatidylinositol-3,4-bisphosphate) to generate PIP3 (phosphatidylinositol-3,4,5-triphosphate) which then binds to Akt via its PH domain, eventually leading to Akt activation^{109,110}. Activated Akt then specifically phosphorylates Mdm2 at position Ser166 which promotes cell survival via Mdm2-mediated inhibition and destruction of p53¹⁰⁹. This cell survival pathway is blocked under stress conditions where Akt is degraded and PI3K is inhibited via phosphatase PTEN (phosphatase and tensin homolog, mean PONDR FIT score of 0.280). The multifarious roles of intrinsic disorder on the functions of PTEN and its interactomes were covered in a recent study¹¹². Particularly, it was shown that PTEN possesses an IDPR at its C-terminus. This disordered C-tail, with its set of MoRFs, conserved eukaryotic linear motifs, and numerous sites of posttranslational modifications, plays a crucial role in a multitude of PTEN-based protein-protein interactions¹¹². Since many proteins in the primary and secondary interactomes of PTEN possessed significant amount of intrinsic disorder, and since many of these PTEN-interacting IDPs were cancer-related, it has been concluded that PTEN represents a pliable, intrinsically disordered, cancer-related hub located within a flexible network of cancer-related IDPs¹¹².

One of the most important mechanisms defining the ability of p53 to possess various regulatory functions consists of the precise control of its posttranslational modifications (PTMs), such as phosphorylation, acetylation, sumoylation, and ubiquitination. For example, in response to DNA damage, the cell cycle checkpoint kinases 1 and 2 (Chk1 and Chk2, mean PONDR FIT scores of 0.252 and 0.343, respectively) become activated by ataxia-telangiectasia and Rad3 related kinase (ATR, mean PONDR FIT score of 0.170) and ataxia-telangiectasia mutated kinase (ATM, mean PONDR FIT score of 0.194), respectively. Activated Chk1 and Chk2 phosphorylate p53 at multiple positions, with Chk1 phosphorylating multiple sites within the intrinsically disordered C-terminus of p53¹¹³ and Chk2 primarily targeting the intrinsically disordered N-terminal region of p53¹¹⁴. It is important to note that the Chk2-induced p53 phosphorylation at Ser20 and ATM-driven p53 phosphorylation at position Ser15 stabilize p53 and promote accumulation of activated p53 in the nucleus¹¹⁴. Activated p53 binds to the consensus p53 response elements of several genes, particularly those encoding proteins from both the extrinsic and intrinsic apoptotic pathways^{103,104}.

In the intrinsic apoptotic pathway, p53 induces the expression of several members of the BCL-2 family (whose family members are classified on the basis of their structural similarity to the BH (BCL-2 homology) domains (BH1, BH2, BH3, and BH4) and a transmembrane domain), such as multidomain BCL-2 family member BAX (mean PONDR FIT score of 0.310)¹¹⁵, together with the BH3-only BCL-2 family members PUMA (p53-upregulated modulator of apoptosis, mean PONDR FIT score of 0.896)¹¹⁶, NOXA (mean PONDR FIT score of 0.578)¹¹⁷, and BID (BH3 interacting domain death agonist, mean PONDR FIT score of 0.374)¹¹⁸.

Under stress conditions, homodimeric BAX undergoes a conformation change that causes translocation to the mitochondrial membrane and formation of higher BAX oligomers. Multimerization of BAX and subsequent translocation to mitochondria are promoted by a family of PUMA proteins produced via the alternative splicing of a p53 transactivation target gene, *PUMA*¹¹⁶. Another p53 target gene, *Noxa* encodes a BH3-only protein, which contributes to the p53-controlled apoptosis in a similar manner to PUMA and BAX. Also, there is another p53 target gene encoding for the p53-regulated apoptosis-inducing protein 1 (p53AIP1, mean PONDR FIT score of 0.492), which is located in the mitochondrial membrane and is directly involved in the p53-dependent mitochondrial apoptosis¹¹⁹. Translocation of BAX to the mitochondrion membrane initiates the release of cytochrome *c* (mean PONDR FIT score of 0.327). At the next stage, the apoptosome complex comprising of cytochrome *c*, the oligomeric form of the apoptotic protease-activating factor-1 (APAF1, mean PONDR FIT score of 0.153), and procaspase-9 (mean PONDR FIT score of 0.271) is formed. This complex then activates caspase-9, which promotes the activation of caspase-3 (mean PONDR FIT score of 0.303), caspase-6 (mean PONDR FIT score of 0.233), and caspase-7 (mean PONDR FIT score of 0.221), leading to the subsequent cleavage of vital death substrates and culminating in cell death.

The p53-stimulated extrinsic apoptotic pathway relies on the engagement of the specific cell-surface death receptors from the TNDR family needed for the activation of specific caspases, such as caspase-8 (mean PONDR FIT score of 0.178) and caspase-3 (mean PONDR FIT score of 0.303), leading to the eventual induction of apoptosis. Among the most common death receptors involved in extrinsic apoptosis are TNDR superfamily member 6 or apoptosis-mediating surface antigen FAS (FAS, CD95, or Apo-1, mean PONDR FIT score of 0.281), death receptor-5 (DR5, mean PONDR FIT score of 0.437), and p53 apoptosis effector related to PMP-22 (PERP, mean PONDR FIT score of 0.215). FAS is activated by binding its ligand, FasL (mean PONDR FIT score of 0.394), which is a homotrimeric protein expressed predominantly by T-cells that causes FAS oligomerization on binding. FAS oligomerization is accompanied by the clustering of their death domains and the formation of the death-inducing signaling complex (or DISC) comprising of FAS (mean PONDR FIT score of 0.281), FADD (mean PONDR FIT score of 0.274), death ligand (mean PONDR FIT score of 0.448), and procaspase-8 (mean PONDR FIT score of 0.301) that binds to the death effector domain of FADD via a homologous motif^{120,121}.

In relation to the p53-mediated extrinsic apoptotic pathway, p53 plays a dual role in FAS-induced apoptosis. Firstly, in response

to the gamma-irradiation of specific tissues, FAS mRNA expression is induced by p53 binding to the specific elements within the promoter and first intron of the *FAS* gene. Secondly, overexpressed p53 can rapidly sensitize cells to FAS-induced apoptosis before the transcription-dependent effect operates, by increasing FAS levels at the cell surface via the promotion of the FAS receptor trafficking from the Golgi apparatus^{120,121}.

The second member of the TNDR family induced by p53 is the death-domain-containing receptor for TNF-related apoptosis-inducing ligand (TRAIL, mean PONDR FIT score of 0.349), killer or death receptor-5 (DR5, mean PONDR FIT score of 0.437). In response to DNA damage, DR5 is induced by p53 in a cell type specific manner, initiating apoptosis through caspase-8. Finally, the p53 apoptosis effector related to PMP-22 (PERP, mean PONDR FIT score of 0.215) is assumed to serve as a direct p53 target, since the *PERP* promoter contains a p53-responsive element and since PERP production is induced in response to DNA damage. PERP is a member of the PMP-22/Gas family of tetraspan transmembrane proteins implicated in the regulation of cell growth. Although the precise role of PERP in p53-mediated apoptosis is yet to be understood, this protein can be involved in at least three potential mechanisms. First, PERP could serve as a cell death receptor that receives specific apoptosis-initiating signals. Second, due to its sequence similarity to the calcium channel, PERP could possess channel or pore activity and play a role in apoptosis activation by passing through some crucial molecules. Third, PERP might directly affect some regulators of apoptotic machinery, such as BAX (mean PONDR FIT score of 0.310) or BCL-2 (mean PONDR FIT score of 0.347), or even directly act on some crucial apoptotic effectors, such as the caspases^{122,123}.

To further delve into the abundance and functional roles of intrinsic disorder in the proteins discussed above from the intrinsic and extrinsic apoptotic pathways mediated by p53, Figure 3–Figure 8 represent disorder profiles plotted using the results of the analysis of these proteins by PONDR-FIT and PONDR® VLXT disorder predictors, and also shows the results of the functional analysis of these proteins using the STRING database⁹². Figure 3–Figure 8 show that all the members of the p53-controlled intrinsic and extrinsic apoptosis signaling pathways possess noticeable amounts of intrinsic disorder and are involved in multiple interactions with other apoptosis-related proteins (and also with many other proteins not directly related to the apoptosis), which are often predicted to be disordered. In protein-protein interaction networks, the highly connected nodes (proteins) with many edges (interactions) are known as hubs. Earlier analysis revealed that protein intrinsic disorder is crucial for the binding promiscuity of hub proteins^{37,124}. In fact, it has been shown that although hub proteins can be entirely disordered or contain long IDPRs or be highly structured, they utilize intrinsic disorder for protein-protein interactions via at least two mechanisms: one disordered region binding to many partners or many disordered region binding to one partner^{37,124–132}. Therefore, in agreement with these previous studies, our analysis revealed that the major players of the p53-modulated apoptosis can be considered as disordered hub proteins.

One should remember, however, that the interactomes of various proteins involved in the regulation and execution of p53-mediated




Figure 3. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and STRING analysis (lower characters) of their interactomes: **group I. A.** and **a.** Growth/survival factor (Fibroblast growth factor 1, UniProt ID: P05230); **B.** and **b.** TRAIL (UniProt ID: P50591); **C.** and **c.** FasL (UniProt ID: P48023); **D.** and **d.** Growth factor receptor (Fibroblast growth factor receptor 2, UniProt ID: P21802); **E.** and **e.** PERP (UniProt ID: Q96FX8). Intrinsic disorder propensity was evaluated by PONDNR-FIT (red curves and pink shadow) and PONDNR® VLXT (blue curves). The shadow around PONDNR-FIT curves represents distribution of statistical errors. STRING database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 4. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and **STRING** analysis (lower characters) of their interactomes: **group II**. **A.** and **a.** DR5 (UniProt ID: O14763); **B.** and **b.** FAS (UniProt ID: P25445); **C.** and **c.** PI3K regulatory subunit (UniProt ID: O00459); **D.** and **d.** PI3K catalytic subunit (UniProt ID: P42336); **E.** and **e.** PTEN (UniProt ID: P60484). Intrinsic disorder propensity was evaluated by POND-R-FIT (red curves and pink shadow) and POND-R[®] VLXT (blue curves). The shadow around POND-R-FIT curves represents distribution of statistical errors. **STRING** database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, **STRING** produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 5. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and STRING analysis (lower characters) of their interactomes: group III. A. and a. AKT1 (UniProt ID: P31749); B. and b. Procaspase-8 (UniProt ID: Q14790); C. and c. Caspase-8 (residues 217–374 and 385–479; ID: Q14790); D. and d. Mdm2 (UniProt ID: Q00987); E. and e. ATM (UniProt ID: Q13315). Intrinsic disorder propensity was evaluated by POND-R-FIT (red curves and pink shadow) and POND-R® VLXT (blue curves). The shadow around POND-R-FIT curves represents distribution of statistical errors. STRING database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 6. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and STRING analysis (lower characters) of their interactomes: group IV. A. and a. ATR (UniProt ID: Q13535); B. and b. p53 (UniProt ID: P04637); C. and c. CHK2 (UniProt ID: O96017); D. and d. CHK1 (UniProt ID: O14757); E. and e. Caspase-3 (UniProt ID: P42574). Intrinsic disorder propensity was evaluated by PONDNR-FIT (red curves and pink shadow) and PONDNR[®] VLXT (blue curves). The shadow around PONDNR-FIT curves represents distribution of statistical errors. STRING database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 7. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and STRING analysis (lower characters) of their interactomes: **group V. A.** and **a.** Caspase-6 (UniProt ID: P55212); **B.** and **b.** Caspase-9 (UniProt ID: P55211); **C.** and **c.** BID (UniProt ID: P55957); **D.** and **d.** p53PAI-1 (UniProt ID: Q9HCN2); **E.** and **e.** NOXA (UniProt ID: Q13794). Intrinsic disorder propensity was evaluated by PONDNR-FIT (red curves and pink shadow) and PONDNR[®] VLXT (blue curves). The shadow around PONDNR-FIT curves represents distribution of statistical errors. STRING database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 8. Intrinsic disorder (upper characters) of some human proteins involved in the p53-mediated apoptotic signaling pathways and STRING analysis (lower characters) of their interactomes: group VI. **A.** and **a.** BAX (UniProt ID: Q07812); **B.** and **b.** BCL-2 (UniProt ID: P10415); **C.** and **c.** PUMA (UniProt ID: Q96PG8); **D.** and **d.** Cytochrome c (UniProt ID: P99999); **E.** and **e.** APAF-1 (UniProt ID: O14727). Intrinsic disorder propensity was evaluated by POND-R-FIT (red curves and pink shadow) and POND-R[®] VLXT (blue curves). The shadow around POND-R-FIT curves represents distribution of statistical errors. STRING database is the online database resource search tool for the Retrieval of Interacting Genes, which provides both experimental and predicted interaction information⁹². For each protein, STRING produces the network of predicted associations for a particular group of proteins. The network nodes are proteins. The edges represent the functional associations evaluated based on experiments, search of databases, and text mining. The thickness of edges is proportional to the confidence level⁹².




Figure 10. Structural characterization of human proteins involved in the p53-mediated apoptotic signaling pathways. **A.** Fibroblast growth factor 1 (PDB ID: 2RQ9); **B.** TRAIL (PDB ID: 1DG6); **C.** Fibroblast growth factor receptor 2 (residues 153–362; PDB ID: 1DJS); **D.** Fibroblast growth factor receptor 2 (residues 465–768; PDB ID: 1GJO); **E.** DR5 (PDB ID: 1D4V); **F.** FAS (Residues 17–172; PDB ID: 3THM); **G.** FAS (Residues 218–335; PDB ID: 1DDF); **H.** PI3K (regulatory subunit, 1–80; PDB ID: 2KT1); **I.** PI3K (regulatory 108–298; PDB ID: 2XS6); **J.** PI3K (regulatory subunit, 433–610; PDB ID: 3MTT); **K.** PI3K (catalytic subunit; PDB ID: 2RD0).




Figure 11. Structural characterization of human proteins involved in the p53-mediated apoptotic signaling pathways: group I. **A.** PTEN (PDB ID: 1D5R); **B.** AKT1 (PDB ID: 3O96); **C.** Caspase-8 (PDB ID: 2K7Z); **D.** Caspase-3 (PDB ID: 1CP3); **E.** Caspase-6 (PDB ID: 2WDP); **F.** Caspase-9 (Residues 1–96; PDB ID: 3YGS); **G.** Caspase-9 (Residues 140–416; PDB ID: 1JXQ).




Figure 12. Structural characterization of human proteins involved in the p53-mediated apoptotic signaling pathways: group II. A. CHK2 (PDB ID: 3I6W); B. CHK1 (PDB ID: 1IA8); C. BID (PDB ID: 2BID); D. NOXA (PDB ID: 3MQP); E. BAX (PDB ID: 1F16); F. BCL-2 (PDB ID: 1G5M).




Figure 13. Structural characterization of human proteins involved in the p53-mediated apoptotic signaling pathways: group III. A. Cytochrome c (PDB ID: 1J3S); B. APAF-1 (Residues 1–591; PDB ID: 1Z6T); C. APAF-1 (PDB ID: 3J2T).




Figure 14. Structural characterization of human proteins involved in the p53-mediated apoptotic signaling pathways: group IV. **A.** Residues 1–93 of p53 (red ribbon) in a complex with the bromodomain of CREB-binding protein (blue surface) (PDB ID: 2LY4); **B.** Residues 94–293 of p53 in a complex with DNA (red bonds) (PDB ID: 3IGK); **C.** Residues 319–360 of p53 in a homotetrameric complex (PDB ID: 1OLH); **D.** Residues 367–386 of p53 (red ribbon) in a complex with the bromodomain of CREB-binding protein (blue surface) (PDB ID: 1JSP); **E.** Residues 1–117 of MDM2 (PDB ID: 1Z1M); **F.** Residues 17–125 of MDM2 (blue surface) in a complex with the transactivation domain of p53 (residues 15–29, red ribbon) (PDB ID: 1YCR); **G.** Residues 147–150 of Mdm2 (red ribbon) in a complex with the N-terminal domain of HAUSP/USP7 (blue surface) (PDB ID: 2FOP); **H.** Residues 290–335 of Mdm2 (PDB ID: 2C6A).

the human proteins associated with the p53-mediated apoptotic signaling pathways possess noticeable conformational flexibility. This is evidenced by the following facts:

- Crystallization of a full length protein was often impossible and many structures shown in [Figure 10](#)–[Figure 14](#) correspond to the protein domains and short fragments;
- Proteins of interest and their fragments were frequently co-crystallized in the complexes with specific binding partners;
- Proteins or protein fragments often do not possess globular shape suggesting that the resulting structures are induced by binding to specific partners (e.g., [Figure 10E](#), [10F](#), [10J](#), [Figure 14A](#), [14C](#), [14D](#), [14F](#), and [14G](#));
- The NMR structures are characterized by the “fuzzy” appearance typical of the highly dynamic structures (e.g., see [Figure 10A](#), [10H](#), [Figure 11C](#), [Figure 12E](#), [Figure 13A](#), [Figure 14E](#), and [14H](#));
- Many proteins contain long structureless tails and loops (e.g., see [Figure 10B](#), [10G](#), [Figure 11A](#), [11E](#), [11G](#), [Figure 12B](#), [12C](#), [12D](#), and [12F](#));

f) Even the determined structures of many proteins contain structurally undefined regions known as regions of missing electron density (see [Table 1](#)). The flexibility or disorder of a protein region determines the failure of this region to scatter X-ray coherently and therefore explains the invisibility of this region in a crystal structure¹³⁴.

All these observations provide strong support to the notions that intrinsic disorder is abundant in human proteins associated with the p53-mediated apoptotic signaling pathways and that disordered regions are frequently used for protein-protein interactions needed for the efficient control and regulation of the mentioned pathways.

Abundance of the disorder-based binding sites in human proteins associated with the p53-mediated apoptotic signaling pathways

IDPs and IDPRs are commonly engaged in protein-protein interactions and play crucial roles in molecular recognition^{2,8,10,30,84,135–143}. In the process of their function and interaction with their binding partners, many IDPs and IDPRs are known to undergo at least partial disorder-to-order transitions, and these conformational

Table 1. Regions of missing electron density in human proteins involved in the p53-mediated apoptotic pathways.

Protein name	PDB ID	Regions of missing electron density
TRAIL	1DG6	91–119, 131–141, 195–196
Fibroblast growth factor receptor 2	1DJS 1GJO	297–306 453–466, 504–506, 581–595, 766–768
FAS	3THM	1–35, 92–93, 122–164
PI3K (regulatory subunit)	2XS6	85–108, 202–203, 257–274, 295–298
PI3K (catalytic subunit)	2RD0	1–7, 307–324, 415–423, 506–527, 941–950, 1051–1068
PTEN	1D5R	7–13, 282–285, 309–312, 352–353
AKT	3O96	46–48, 89–91, 114–144, 189–198, 299–312, 430–443
Caspase-3	1CP3	1–34, 174–184
Caspase-6	2WDP	1–30, 166–199, 262–266
Caspase-9	1JXQ	139–147, 296–297, 404–409
Chk2	3I6W	70–91, 228–232, 254–267, 370–401, 502–512
Chk1	1IA8	1, 46–47, 277–289
BCL2	1GM5	1–2
APAF-1	1Z6T	95–104, 587–591

transitions are crucial for recognition, regulation, and signaling^{4,8,84,143–149}. Based on the specific features and patterns in the per-residue disorder propensity curves calculated by the PONDR® VLXT tool combined with the analysis of several characteristic sequence-based parameters, short disordered regions capable of undergoing the disorder-to-order transitions on binding can be found by specific predictors^{84,85}. These disorder-based binding regions are known as α -helix forming MoRFs (α -MoRFs). Table 2 shows that α -MoRFs are common in human proteins involved in p53-mediated apoptotic pathways, and that some long disordered proteins have multiple α -MoRFs, which likely serve as promiscuous binders interacting with multiple partners.

Another way to find potential disorder-based binding sites is based on looking for residues in disordered regions that cannot form enough favorable intra-chain interactions to fold on their own, but which are likely to gain stabilizing energy by interacting with a globular protein partner^{86,87}. This approach is based on using the ANCHOR algorithm^{86,87} to find disordered but foldable binding regions, ANCHOR-identified binding sites (AIBSs). ANCHOR relies on the pairwise energy estimation approach that is the basis for IUPred, a general disorder prediction method⁸², whereas MoRF identifiers rely on specific patterns in the per-residue disorder propensity curves calculated by the PONDR® VLXT⁷⁸. Since methodologically and logistically ANCHOR and MoRF identifiers are very different, the application of both tools provides complementary information. Table 2 shows that AIBSs are very common among the human proteins involved in the p53-mediated apoptotic pathways. In fact, the majority of these proteins possess more than one AIBS, and many of them have multiple AIBSs. Furthermore, there is typically a reasonable agreement between the outputs of these two tools.

Finally, Table 2 lists some of the experimentally validated binding sites found in the human proteins involved in the p53-mediated

apoptotic pathways. These potential binding sites were typically found based on the analysis of the reported x-ray crystallography or NMR data on structural characterization of a fragment of a target protein bound to its partner(s). Table 2 shows that the majority of the experimentally found binding sites are correctly predicted by at least one algorithm. This observation provides indirect support to the validity of the results of the computational analysis and to the conclusion that the major function of many IDPRs in the human proteins involved in the p53-mediated apoptotic pathways is related to regulation and control via the protein-protein interactions.

Concluding remarks

In conclusion, the results presented in this paper clearly show that many of the human proteins involved in regulation and execution of three major programmed cell death pathways: apoptosis, autophagy, and necroptosis, as well as human proteins that are involved in the p53-mediated apoptotic signaling pathways possess substantial amounts of intrinsic disorder. Since functional repertoires of ordered and disordered proteins are very different, finding high prevalence of disorder in PCD-related proteins clearly indicates that careful consideration of this important feature is absolutely critical for better understanding the structure and conformational behavior of these proteins, their promiscuity, and molecular mechanisms of their functions, regulation, and control. In agreement with this idea, we show here that most major players in three major PCD pathways and in particular proteins related to the p53-mediated apoptosis have relative high levels of intrinsic disorder and that there is a positive relationship between protein disorder and the number of interactions a protein has. Furthermore, many of these proteins contain multiple disorder-based protein interaction sites. These observations suggest that intrinsic disorder might be intimately related to all the aspects of activity of these proteins and plays indispensable roles in their functional interactions.

Table 2. Abundance of disorder-based binding sites in proteins involved in the p53-mediated apoptotic pathways.

Protein name	UniProt ID	MoRF	AIBS ^a	Experiment	Reference
Fibroblast growth factor 1	P05230	-	28–39	24–27 (NLS) ^b	UniProt
TRAIL	P50591	-	<i>179–189</i>		
FasL	P48023	4–21, 83–101, 133–150	9–19, <i>77–110</i>	81–102	UniProt
Fibroblast growth factor receptor 2	P21802	-	<i>7–12, 117–126, 171–178, 380–396, 488–498, 756–761, 808–812</i>	764–778	[153]
PERP	Q96FX8	-	<i>1–15, 177–190</i>	-	-
DR5	O14763	37–55, 100–118, 165–182	6–15, 34–57, <i>214–247, 272–279, 302–312, 339–352</i>	-	-
FAS	P25445	-	<i>1–15, 177–190</i>	230–254	UniProt
PI3K regulatory subunit	O00459	487–504, 565–582	29–43, 70–84, 109–118, 122–136, 169–183, 218–231, 241–256, 277–298, 312–320, 325–335, 395–400, <i>484–488, 574–581</i>	-	-
PTEN	P60484	386–403	<i>316–320, 336–350, 376–380, 397–403</i>	391–403	UniProt
AKT1	P31749	414–431	<i>56–60, 73–84, 151–155, 406–414, 441–447, 471–480</i>	-	-
Procaspase-8	Q14790	228–245	<i>233–242, 399–404, 421–426, 440–444, 472–479</i>	-	-
Mdm2	Q00987	187–205, 228–245, 270–287, 338–356	100–108, 189–208, 235–261, 273–284, 296–306, 322–329, 359–367, 399–409	145–150, 179–185, 190–202, 223–232	[154], UniProt
ATM	Q13315	1–18, 1992–2009	<i>1–12, 60–64, 896–907, 2558–2563, 2622–2632, 2950–2957</i>	1373–1382	UniProt
ATR	Q13535	-	<i>2634–2638</i>	-	-
p53	P04637	17–35, 321–338, 374–398	11–57, 106–115, 132–141, 232–239, 251–258, 265–277, 322–355, 363–387	13–29, 1–39, 33–60, 241–288, 273–280, 326–356, 359–363, 367–388	UniProt, [155–159]
CHK2	O96017	526–543	1–26, 35–41, 58–74, 94–110, <i>415–419, 535–543</i>	63–73	[160]
CHK1	O14757	285–302, 333–350	<i>240–244, 294–300, 334–342</i>	-	-
Caspase-3	P42574	115–133	41–53, 114–119	-	-
Caspase-6	P55212	19–37	-	-	-
Caspase-9	P55211	-	71–77, 281–286	-	-
BID	P55957	-	<i>17–27, 86–90, 105–111, 148–157</i>	76–109	[161]
p53PAI-1	Q9HCN2	8–25	8–17	-	-
NOXA	Q13794	-	<i>38–54</i>	19–43	UniProt
BAX	Q07812	21–38	18–34	13–19, 48–81	[162,163]
BCL-2	P10415	-	13–32, 46–51	-	-
PUMA	Q96PG8	12–30, 174–192, 231–248	1–11, 15–29, 61–80, 85–99, 102–119, 123–261	-	-
Cytochrome c	P99999	-	9–18	-	-

^a ANCHOR-indicated binding site. Numbers shown in italic correspond to regions (longer than 5 residues) that were predicted as potential binding site by ANCHOR, but filtered due to low IUPred disorder scores (below 0.1)^{66,87}.

^b NLS, Nuclear localization signal.

MoRF, Molecular recognition feature.

List of abbreviations

AIBS, ANCHOR-indicated binding site
 AIF, apoptosis inducing factor
 APAF1, apoptotic protease-activating factor 1
 ATM, ataxia-telangiectasia mutated kinase
 ATR, ataxia-telangiectasia and Rad3 related kinase
 BID, BH3-interacting domain death agonist
 Chk1, cell cycle checkpoint kinase 1
 Chk2, cell cycle checkpoint kinase 2
 DAPK, death-associated protein kinase
 DISC, death-inducing signaling complex
 DR5, death receptor-5
 FADD, FAS-associated death domain protein
 FasL, FAS ligand
 FGFR2, fibroblast growth factor receptor 2
 GFG1, fibroblast growth factor 1
 HMGN1, high-mobility group box 1
 IAP, inhibitor of apoptosis protein
 IDP, intrinsically disordered protein
 IDPR, intrinsically disordered protein region
 JNK, c-Jun N-terminal kinase
 Mdm2, mouse double minute-2 ubiquitin ligase
 MoRF, molecular recognition feature
 mTOR, mammalian target of rapamycin kinase
 p53AIP1, p53-regulated apoptosis-inducing protein 1
 PAR, polyADP-ribose
 PARP1, poly-ADP-ribose polymerase 1
 PE, phosphatidylethanolamine
 PERP, p53 apoptosis effector related to PMP-22
 PCD, programmed cell death
 PDB, protein databank
 PI3K, phosphoinositol 3-kinase
 PIP2, phosphatidylinositol-3,4-bisphosphate

PTEN, Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
 PTM, posttranslational modification
 RIPK1, receptor-interacting protein kinase 1
 SMAC, second mitochondria-derived activator of caspase
 TNDR, tumor necrosis factor receptor
 TNFR1, tumor necrosis factor receptor 1
 TRADD, tumor necrosis factor receptor type 1-associated DEATH domain protein
 TRAF, TNF receptor-associated factor
 TRAIL, TNF-related apoptosis-inducing ligand
 TRAIL-R, TNF-related apoptosis-inducing ligand receptor

Author contributions

AVU implemented experiments, performed analysis, generated figures, and helped with manuscript drafting. BX and ZP implemented experiments and performed analysis. LK helped in experiment design and participated in the manuscript drafting. VNU proposed the idea of the study, designed and implemented experiments, carried out the analysis, drafted the manuscript, and coordinated study.

Competing interests

Authors have no competing interests.

Grant information

This work was supported in part by University of South Florida (V.N.U. and B.X.), Temple University (A.V.U.), the Programs of the Russian Academy of Sciences for the “Molecular and Cellular Biology” (to V.N.U.), the Alberta Innovates Graduate Scholarship in Omics (to Z.P.), and the Natural Sciences and Engineering Research Council (NSERC) Discovery grant (to L.K.).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Dunker AK, Obradovic Z, Romero P, *et al.*: **Intrinsic protein disorder in complete genomes.** *Genome Inform Ser Workshop Genome Inform.* 2000; **11**: 161–171. [PubMed Abstract](#)
2. Uversky VN, Dunker AK: **Understanding protein non-folding.** *Biochim Biophys Acta.* 2010; **1804**(6): 1231–1264. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Ward JJ, Sodhi JS, McGuffin LJ, *et al.*: **Prediction and functional analysis of native disorder in proteins from the three kingdoms of life.** *J Mol Biol.* 2004; **337**(3): 635–645. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Uversky VN, Gillespie JR, Fink AL: **Why are “natively unfolded” proteins unstructured under physiologic conditions?** *Proteins.* 2000; **41**(3): 415–427. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Xue B, Dunker AK, Uversky VN: **Orderly order in protein intrinsic disorder distribution: disorder in 3500 proteomes from viruses and the three domains of life.** *J Biomol Struct Dyn.* 2012; **30**(2): 137–149. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Dunker AK, Garner E, Guillot S, *et al.*: **Protein disorder and the evolution of molecular recognition: theory, predictions and observations.** *Pac Symp Biocomput.* 1998; 473–484. [PubMed Abstract](#)
7. Wright PE, Dyson HJ: **Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm.** *J Mol Biol.* 1999; **293**(2): 321–331. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Dunker AK, Lawson JD, Brown CJ, *et al.*: **Intrinsically disordered protein.** *J Mol Graph Model.* 2001; **19**(1): 26–59. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Tompa P: **Intrinsically unstructured proteins.** *Trends Biochem Sci.* 2002; **27**(10): 527–533. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Daughdrill GW, Pielak GJ, Uversky VN, *et al.*: **Natively disordered proteins.** In: Buchner J, Kiefhaber T(eds) *Handbook of Protein Folding.* Wiley-VCH, Verlag GmbH & Co., Weinheim, Germany, 2005; pp 271–353. [Publisher Full Text](#)
11. Uversky VN: **Natively unfolded proteins: a point where biology waits for physics.** *Protein Sci.* 2002; **11**(4): 739–756. [PubMed Abstract](#) | [Free Full Text](#)
12. Uversky VN: **The mysterious unfoldome: structureless, underappreciated, yet vital part of any given proteome.** *J Biomed Biotechnol.* 2010; **2010**: 568068. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Uversky VN, Oldfield CJ, Dunker AK: **Intrinsically disordered proteins in human diseases: introducing the D2 concept.** *Annu Rev Biophys.* 2008; **37**: 215–246. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Lee H, Mok KH, Muhandiram R, *et al.*: **Local structural elements in the mostly unstructured transcriptional activation domain of human p53.** *J Biol Chem.* 2000; **275**(38): 29426–29432. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Adkins JN, Lumb KJ: **Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2.** *Proteins.* 2002; **46**(1): 1–7. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Chang BS, Minn AJ, Muchmore SW, *et al.*: **Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2.** *EMBO J.* 1997; **16**(5): 968–977. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Campbell KM, Terrell AR, Laybourn PJ, *et al.*: **Intrinsic structural disorder of the C-terminal activation domain from the bZIP transcription factor Fos.** *Biochemistry.* 2000; **39**(10): 2708–2713. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Sunde M, McGrath KC, Young L, *et al.*: **TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer.** *Cancer Res.* 2004; **64**(8): 2766–2773. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Zeng Y, He Y, Yang F, *et al.*: **The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.** *J Biol Chem.* 2011; **286**(16): 13985–13994. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Glenner GG, Wong CW: **Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein.** *Biochem Biophys Res Commun.* 1984; **122**(3): 1131–1135. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Masters CL, Multhaup G, Simms G, *et al.*: **Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels.** *EMBO J.* 1985; **4**(11): 2757–2763. [PubMed Abstract](#) | [Free Full Text](#)
22. Lee VM, Balin BJ, Otvos L Jr, *et al.*: **A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.** *Science.* 1991; **251**(4994): 675–678. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Ueda K, Fukushima H, Masliah E, *et al.*: **Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.** *Proc Natl Acad Sci U S A.* 1993; **90**(23): 11282–11286. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Wisniewski KE, Dalton AJ, McLachlan C, *et al.*: **Alzheimer's disease in Down's syndrome: clinicopathologic studies.** *Neurology.* 1985; **35**(7): 957–961. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Dev KK, Hofele K, Barbieri S, *et al.*: **Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.** *Neuropharmacology.* 2003; **45**(1): 14–44. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Prusiner SB: **Shattuck lecture—neurodegenerative diseases and prions.** *N Engl J Med.* 2001; **344**(20): 1516–1526. [PubMed Abstract](#) | [Publisher Full Text](#)
27. Zoghbi HY, Orr HT: **Polyglutamine diseases: protein cleavage and aggregation.** *Curr Opin Neurobiol.* 1999; **9**(5): 566–570. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Uversky VN: **Amyloidogenesis of natively unfolded proteins.** *Curr Alzheimer Res.* 2008; **5**(3): 260–287. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Iakoucheva LM, Brown CJ, Lawson JD, *et al.*: **Intrinsic disorder in cell-signaling and cancer-associated proteins.** *J Mol Biol.* 2002; **323**(3): 573–584. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Radivojac P, Iakoucheva LM, Oldfield CJ, *et al.*: **Intrinsic disorder and functional proteomics.** *Biophys J.* 2007; **92**(5): 1439–1456. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Cheng Y, LeGall T, Oldfield CJ, *et al.*: **Abundance of intrinsic disorder in protein associated with cardiovascular disease.** *Biochemistry.* 2006; **45**(35): 10448–10460. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Uversky VN, Oldfield CJ, Midic U, *et al.*: **Unfoldomics of human diseases: linking protein intrinsic disorder with diseases.** *BMC Genomics.* 2009; **10**(Suppl 1): S7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Uversky VN: **Intrinsic disorder in proteins associated with neurodegenerative diseases.** *Front Biosci (Landmark Ed).* 2009; **14**: 5188–5238. [PubMed Abstract](#) | [Publisher Full Text](#)
34. Mohan A, Sullivan WJ Jr, Radivojac P, *et al.*: **Intrinsic disorder in pathogenic and non-pathogenic microbes: discovering and analyzing the unfoldomes of early-branching eukaryotes.** *Mol Biosyst.* 2008; **4**(4): 328–340. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Midic U, Oldfield CJ, Dunker AK, *et al.*: **Protein disorder in the human diseaseome: Unfoldomics of human genetic diseases.** *BMC Genomics.* 2009; **10**(Suppl 1): S12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Rajagopalan K, Mooney SM, Parekh N, *et al.*: **A majority of the cancer/testis antigens are intrinsically disordered proteins.** *J Cell Biochem.* 2011; **112**(11): 3256–3267. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Dunker AK, Cortese MS, Romero P, *et al.*: **Flexible nets: The roles of intrinsic disorder in protein interaction networks.** *FEBS J.* 2005; **272**(20): 5129–5148. [PubMed Abstract](#) | [Publisher Full Text](#)
38. Oldfield CJ, Cheng Y, Cortese MS, *et al.*: **Comparing and combining predictors of mostly disordered proteins.** *Biochemistry.* 2005; **44**(6): 1989–2000. [PubMed Abstract](#) | [Publisher Full Text](#)
39. Vucetic S, Xie H, Iakoucheva LM, *et al.*: **Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions.** *J Proteome Res.* 2007; **6**(5): 1899–1916. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Xie H, Vucetic S, Iakoucheva LM, *et al.*: **Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions.** *J Proteome Res.* 2007; **6**(5): 1882–1898. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Xie H, Vucetic S, Iakoucheva LM, *et al.*: **Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins.** *J Proteome Res.* 2007; **6**(5): 1917–1932. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Peng Z, Xue B, Kurgan L, *et al.*: **Resilience of death: intrinsic disorder in proteins involved in the programmed cell death.** *Cell Death Differ.* 2013; **20**(9): 1257–1267. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Kaczmarek A, Vandenabeele P, Krysko DV: **Necroptosis: the release of damage-associated molecular patterns and its physiological relevance.** *Immunity.* 2013; **38**(2): 209–223. [PubMed Abstract](#) | [Publisher Full Text](#)
44. Eisenberg-Lerner A, Bialik S, Simon HU, *et al.*: **Life and death partners: apoptosis, autophagy and the cross-talk between them.** *Cell Death Differ.* 2009; **16**(7): 966–975. [PubMed Abstract](#) | [Publisher Full Text](#)
45. He C, Klionsky DJ: **Regulation mechanisms and signaling pathways of autophagy.** *Annu Rev Genet.* 2009; **43**: 67–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

46. Liu B, Cheng Y, Liu Q, *et al.*: **Autophagic pathways as new targets for cancer drug development.** *Acta Pharmacol Sin.* 2010; **31**(9): 1154–1164.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Bialik S, Zalckvar E, Ber Y, *et al.*: **Systems biology analysis of programmed cell death.** *Trends Biochem Sci.* 2010; **35**(10): 556–564.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Galluzzi L, Vanden Berghe T, Vanlangenacker N, *et al.*: **Programmed necrosis from molecules to health and disease.** *Int Rev Cell Mol Biol.* 2011; **289**: 1–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Ouyang L, Shi Z, Zhao S, *et al.*: **Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.** *Cell Prolif.* 2012; **45**(6): 487–498.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Tan ML, Ooi JP, Ismail N, *et al.*: **Programmed cell death pathways and current antitumor targets.** *Pharm Res.* 2009; **26**(7): 1547–1560.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Xie Z, Klionsky DJ: **Autophagosome formation: core machinery and adaptations.** *Nat Cell Biol.* 2007; **9**(10): 1102–1109.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Huett A, Goel G, Xavier RJ: **A systems biology viewpoint on autophagy in health and disease.** *Curr Opin Gastroenterol.* 2010; **26**(4): 302–309.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Chen S, Rehman SK, Zhang W, *et al.*: **Autophagy is a therapeutic target in anticancer drug resistance.** *Biochim Biophys Acta.* 2010; **1806**(2): 220–229.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Li ZY, Yang Y, Ming M, *et al.*: **Mitochondrial ROS generation for regulation of autophagic pathways in cancer.** *Biochem Biophys Res Commun.* 2011; **414**(1): 5–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Liu JJ, Lin M, Yu JY, *et al.*: **Targeting apoptotic and autophagic pathways for cancer therapeutics.** *Cancer Lett.* 2011; **300**(2): 105–114.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Henriquez M, Armissen R, Stutzin A, *et al.*: **Cell death by necrosis, a regulated way to go.** *Curr Mol Med.* 2008; **8**(3): 187–206.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Cohen GM: **Caspases: the executioners of apoptosis.** *Biochem J.* 1997; **326**(Pt 1): 1–16.
[PubMed Abstract](#) | [Free Full Text](#)
58. Brune B: **Nitric oxide: NO apoptosis or turning it ON?** *Cell Death Differ.* 2003; **10**(8): 864–869.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Brune B, Zhou J, von Knethen A: **Nitric oxide, oxidative stress, and apoptosis.** *Kidney Int.* 2003; **63**(Suppl 84): S22–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Brune B, Schneiderhan N: **Nitric oxide evoked p53-accumulation and apoptosis.** *Toxicol Lett.* 2003; **139**(2–3): 119–123.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Popov SG, Villasmil R, Bernardi J, *et al.*: **Lethal toxin of Bacillus anthracis causes apoptosis of macrophages.** *Biochem Biophys Res Commun.* 2002; **293**(1): 349–355.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Fridman JS, Lowe SW: **Control of apoptosis by p53.** *Oncogene.* 2003; **22**(56): 9030–9040.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Peter ME, Krammer PH: **The CD95(APO-1/Fas) DISC and beyond.** *Cell Death Differ.* 2003; **10**(1): 26–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Mattson MP, Chan SL: **Calcium orchestrates apoptosis.** *Nat Cell Biol.* 2003; **5**(12): 1041–1043.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Kroemer G, Reed JC: **Mitochondrial control of cell death.** *Nat Med.* 2000; **6**(5): 513–519.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Reed JC, Kroemer G: **Mechanisms of mitochondrial membrane permeabilization.** *Cell Death Differ.* 2000; **7**(12): 1145.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Widlak P, Li LY, Wang X, *et al.*: **Action of recombinant human apoptotic endonuclease G on naked DNA and chromatin substrates: cooperation with exonuclease and DNase I.** *J Biol Chem.* 2001; **276**(51): 48404–48409.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Li LY, Luo X, Wang X: **Endonuclease G is an apoptotic DNase when released from mitochondria.** *Nature.* 2001; **412**(6842): 95–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Parrish J, Li L, Klotz K, *et al.*: **Mitochondrial endonuclease G is important for apoptosis in C. elegans.** *Nature.* 2001; **412**(6842): 90–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Tsujimoto Y: **Cell death regulation by the Bcl-2 protein family in the mitochondria.** *J Cell Physiol.* 2003; **195**(2): 158–167.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Degterev A, Huang Z, Boyce M, *et al.*: **Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury.** *Nat Chem Biol.* 2005; **1**(2): 112–119.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Festjens N, Vanden Berghe T, Vandenabeele P: **Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response.** *Biochim Biophys Acta.* 2006; **1757**(9–10): 1371–1387.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Boujrad H, Gubkina O, Robert N, *et al.*: **AIF-mediated programmed necrosis: a highly regulated way to die.** *Cell Cycle.* 2007; **6**(21): 2612–2619.
[PubMed Abstract](#)
74. Eisenberg-Lerner A, Kimchi A: **DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress.** *Cell Death Differ.* 2007; **14**(11): 1908–1915.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Morgan MJ, Kim YS, Liu ZG: **TNFalpha and reactive oxygen species in necrotic cell death.** *Cell Res.* 2008; **18**(3): 343–349.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Diez J, Walter D, Munoz-Pinedo C, *et al.*: **DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death.** *Cell Death Differ.* 2010; **17**(5): 735–736.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Xue B, Dunbrack RL, Williams RW, *et al.*: **PONDR-FIT: a meta-predictor of intrinsically disordered amino acids.** *Biochim Biophys Acta.* 2010; **1804**(4): 996–1010.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Romero P, Obradovic Z, Li X, *et al.*: **Sequence complexity of disordered protein.** *Proteins.* 2001; **42**(1): 38–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Peng K, Vucetic S, Radivojac P, *et al.*: **Optimizing long intrinsic disorder predictors with protein evolutionary information.** *J Bioinform Comput Biol.* 2005; **3**(1): 35–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Peng K, Radivojac P, Vucetic S, *et al.*: **Length-dependent prediction of protein intrinsic disorder.** *BMC Bioinformatics.* 2006; **7**: 208.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, *et al.*: **FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded.** *Bioinformatics.* 2005; **21**(16): 3435–3438.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Dosztanyi Z, Csizmek V, Tompa P, *et al.*: **IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content.** *Bioinformatics.* 2005; **21**(16): 3433–3434.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Campen A, Williams RM, Brown CJ, *et al.*: **TOP-IDP-scale: a new amino acid scale measuring propensity for intrinsic disorder.** *Protein Pept Lett.* 2008; **15**(9): 956–963.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Oldfield CJ, Cheng Y, Cortese MS, *et al.*: **Coupled folding and binding with alpha-helix-forming molecular recognition elements.** *Biochemistry.* 2005; **44**(37): 12454–12470.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Cheng Y, Oldfield CJ, Meng J, *et al.*: **Mining alpha-helix-forming molecular recognition features with cross species sequence alignments.** *Biochemistry.* 2007; **46**(47): 13468–13477.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Meszaros B, Simon I, Dosztanyi Z: **Prediction of protein binding regions in disordered proteins.** *PLoS Comput Biol.* 2009; **5**(5): e1000376.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Dosztanyi Z, Meszaros B, Simon I: **ANCHOR: web server for predicting protein binding regions in disordered proteins.** *Bioinformatics.* 2009; **25**(20): 2745–2746.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Dosztanyi Z, Csizmek V, Tompa P, *et al.*: **The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins.** *J Mol Biol.* 2005; **347**(4): 827–839.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Peng Z, Mizianty MJ, Xue B, *et al.*: **More than just tails: intrinsic disorder in histone proteins.** *Mol Biosyst.* 2012; **8**(7): 1886–1901.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Kirilyuk A, Shimoji M, Catania J, *et al.*: **An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation.** *Plos One.* 2012; **7**(11): e48243.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Coelho Ribeiro Mde L, Espinosa J, Islam S, *et al.*: **Malleable ribonucleoprotein machine: protein intrinsic disorder in the Saccharomyces cerevisiae spliceosome.** *PeerJ.* 2013; **1**: e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Szklarczyk D, Franceschini A, Kuhn M, *et al.*: **The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored.** *Nucleic Acids Res.* 2011; **39**(Database issue): D561–568.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Peter ME, Krammer PH: **Mechanisms of CD95(APO-1/Fas)-mediated apoptosis.** *Curr Opin Immunol.* 1998; **10**(5): 545–551.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Green DR, Reed JC: **Mitochondria and apoptosis.** *Science.* 1998; **281**(5381): 1309–1312.
[PubMed Abstract](#) | [Publisher Full Text](#)

95. Green D, Kroemer G: **The central executioners of apoptosis: caspases or mitochondria?** *Trends Cell Biol.* 1998; **8**(7): 267–271.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Yin XM: **Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways.** *Cell Res.* 2000; **10**(3): 161–167.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Martinon F, Holler N, Richard C, *et al.*: **Activation of a pro-apoptotic amplification loop through inhibition of NF-kappaB-dependent survival signals by caspase-mediated inactivation of RIP.** *FEBS Lett.* 2000; **468**(2–3): 134–136.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Holler N, Zaru R, Micheau O, *et al.*: **Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.** *Nat Immunol.* 2000; **1**(6): 489–495.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Declercq W, Vanden Berghe T, Vandenabeele P: **RIP kinases at the crossroads of cell death and survival.** *Cell.* 2009; **138**(2): 229–232.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Degterev A, Hitomi J, Gemscheid M, *et al.*: **Identification of RIP1 kinase as a specific cellular target of necrostatins.** *Nat Chem Biol.* 2008; **4**(5): 313–321.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Eisenberg T, Carmona-Gutierrez D, Büttner S, *et al.*: **Necrosis in yeast.** *Apoptosis.* 2010; **15**(3): 257–268.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Scaffidi P, Misteli T, Bianchi ME: **Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.** *Nature.* 2002; **418**(6894): 191–195.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Zhao R, Gish K, Murphy M, *et al.*: **Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.** *Genes Dev.* 2000; **14**(8): 981–993.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Balint EE, Vousden KH: **Activation and activities of the p53 tumour suppressor protein.** *Br J Cancer.* 2001; **85**(12): 1813–1823.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. el-Deiry WS: **Regulation of p53 downstream genes.** *Semin Cancer Biol.* 1998; **8**(5): 345–357.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Yu J, Zhang L, Hwang PM, *et al.*: **Identification and classification of p53-regulated genes.** *Proc Natl Acad Sci U S A.* 1999; **96**(25): 14517–14522.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Sax JK, El-Deiry WS: **p53-induced gene expression analysis.** *Methods Mol Biol.* 2003; **234**: 65–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Anderson CW, Appella E: **Signaling to the p53 tumor suppressor through pathways activated by genotoxic and nongenotoxic stress.** In: Bradshaw RA, Dennis EA (eds) *Handbook of Cell Signaling*. Academic Press, New York, 2004; pp 237–247.
109. Gottlieb TM, Leal JF, Seger R, *et al.*: **Cross-talk between Akt p53 and Mdm2: possible implications for the regulation of apoptosis.** *Oncogene.* 2002; **21**(8): 1299–1303.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Nicholson KM, Anderson NG: **The protein kinase B/Akt signalling pathway in human malignancy.** *Cell Signal.* 2002; **14**(5): 381–395.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Collins MK, Perkins GR, Rodriguez-Tarduchy G, *et al.*: **Growth factors as survival factors: regulation of apoptosis.** *Bioessays.* 1994; **16**(2): 133–138.
[PubMed Abstract](#) | [Publisher Full Text](#)
112. Malaney P, Pathak RR, Xue B, *et al.*: **Intrinsic Disorder in PTEN and its Interactome Confers Structural Plasticity and Functional Versatility.** *Sci Rep.* 2013; **3**: 2035.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Shieh SY, Ahn J, Tamai K, *et al.*: **The human homologs of checkpoint kinases Chk1 and Cds1(Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.** *Genes Dev.* 2000; **14**(3): 289–300.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Chen L, Gilkes DM, Pan Y, *et al.*: **ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.** *EMBO J.* 2005; **24**(19): 3411–3422.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Miyashita T, Krajewski S, Krajewska M, *et al.*: **Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.** *Oncogene.* 1994; **9**(6): 1799–1805.
[PubMed Abstract](#)
116. Nakano K, Vousden KH: **PUMA, a novel proapoptotic gene, is induced by p53.** *Mol Cell.* 2001; **7**(3): 683–694.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Oda E, Ohki R, Murasawa H, *et al.*: **Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.** *Science.* 2000; **288**(5468): 1053–1058.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Sax JK, Fei P, Murphy ME, *et al.*: **BID regulation by p53 contributes to chemosensitivity.** *Nat Cell Biol.* 2002; **4**(11): 842–849.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Oda K, Arakawa H, Tanaka T, *et al.*: **p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.** *Cell.* 2000; **102**(6): 849–862.
[PubMed Abstract](#) | [Publisher Full Text](#)
120. Meley D, Spiller DG, White MR, *et al.*: **p53-mediated delayed NF-kappaB activity enhances etoposide-induced cell death in medulloblastoma.** *Cell Death Dis.* 2010; **1**: e41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Sharp AN, Heazell AE, Crocker IP, *et al.*: **Placental apoptosis in health and disease.** *Am J Reprod Immunol.* 2010; **64**(3): 159–169.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Amaral JD, Castro RE, Steer CJ, *et al.*: **p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis.** *Trends Mol Med.* 2009; **15**(11): 531–541.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. Davies L, Spiller D, White MR, *et al.*: **PERP expression stabilizes active p53 via modulation of p53-MDM2 interaction in uveal melanoma cells.** *Cell Death Dis.* 2011; **2**: e136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Uversky VN, Oldfield CJ, Dunker AK: **Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.** *J Mol Recognit.* 2005; **18**(5): 343–384.
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Bustos DM, Iglesias AA: **Intrinsic disorder is a key characteristic in partners that bind 14-3-3 proteins.** *Proteins.* 2006; **63**(1): 35–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Radivojac P, Vucetic S, O'Connor TR, *et al.*: **Calmodulin signaling: analysis and prediction of a disorder-dependent molecular recognition.** *Proteins.* 2006; **63**(2): 398–410.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Patil A, Nakamura H: **Disordered domains and high surface charge confer hubs with the ability to interact with multiple proteins in interaction networks.** *FEBS Lett.* 2006; **580**(8): 2041–2045.
[PubMed Abstract](#) | [Publisher Full Text](#)
128. Ekman D, Light S, Bjorklund AK, *et al.*: **What properties characterize the hub proteins of the protein-protein interaction network of Saccharomyces cerevisiae?** *Genome Biol.* 2006; **7**(6): R45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Haynes C, Oldfield CJ, Ji F, *et al.*: **Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes.** *PLoS Comput Biol.* 2006; **2**(8): e100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
130. Dosztanyi Z, Chen J, Dunker AK, *et al.*: **Disorder and sequence repeats in hub proteins and their implications for network evolution.** *J Proteome Res.* 2006; **5**(11): 2985–2995.
[PubMed Abstract](#) | [Publisher Full Text](#)
131. Singh GP, Dash D: **Intrinsic disorder in yeast transcriptional regulatory network.** *Proteins.* 2007; **68**(3): 602–605.
[PubMed Abstract](#) | [Publisher Full Text](#)
132. Singh GP, Ganapathi M, Dash D: **Role of intrinsic disorder in transient interactions of hub proteins.** *Proteins.* 2007; **66**(4): 761–765.
[PubMed Abstract](#) | [Publisher Full Text](#)
133. Berman HM, Westbrook J, Feng Z, *et al.*: **The Protein Data Bank.** *Nucleic Acids Res.* 2000; **28**(1): 235–242.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. Uversky VN, Dunker AK: **Understanding protein non-folding.** *Biochim Biophys Acta.* 2010; **1804**(6): 1231–1264.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
135. Dunker AK, Brown CJ, Lawson JD, *et al.*: **Intrinsic disorder and protein function.** *Biochemistry.* 2002; **41**(21): 6573–6582.
[PubMed Abstract](#)
136. Dunker AK, Brown CJ, Obradovic Z: **Identification and functions of usefully disordered proteins.** *Adv Protein Chem.* 2002; **62**: 25–49.
[PubMed Abstract](#)
137. Tompa P: **Intrinsically unstructured proteins.** *Trends Biochem Sci.* 2002; **27**(10): 527–533.
[PubMed Abstract](#) | [Publisher Full Text](#)
138. Uversky VN, Oldfield CJ, Dunker AK: **Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.** *J Mol Recognit.* 2005; **18**(5): 343–384.
[PubMed Abstract](#) | [Publisher Full Text](#)
139. Dunker AK, Silman I, Uversky VN, *et al.*: **Function and structure of inherently disordered proteins.** *Curr Opin Struct Biol.* 2008; **18**(6): 756–764.
[PubMed Abstract](#) | [Publisher Full Text](#)
140. Dunker AK, Uversky VN: **Signal transduction via unstructured protein conduits.** *Nat Chem Biol.* 2008; **4**(4): 229–230.
[PubMed Abstract](#) | [Publisher Full Text](#)
141. Uversky VN: **Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes.** *Chem Soc Rev.* 2011; **40**(3): 1623–1634.
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Uversky VN: **Disordered competitive recruiter: fast and foldable.** *J Mol Biol.*

- 2012; **418**(5): 267–268.
[PubMed Abstract](#) | [Publisher Full Text](#)
143. Uversky VN: **Intrinsic Disorder-based Protein Interactions and their Modulators.** *Curr Pharm Des.* 2013; **19**(23): 4191–4213.
[PubMed Abstract](#) | [Publisher Full Text](#)
144. Dyson HJ, Wright PE: **Coupling of folding and binding for unstructured proteins.** *Curr Opin Struct Biol.* 2002; **12**(1): 54–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
145. Dyson HJ, Wright PE: **Intrinsically unstructured proteins and their functions.** *Nat Rev Mol Cell Biol.* 2005; **6**(3): 197–208.
[PubMed Abstract](#) | [Publisher Full Text](#)
146. Wright PE, Dyson HJ: **Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm.** *J Mol Biol.* 1999; **293**(2): 321–331.
[PubMed Abstract](#) | [Publisher Full Text](#)
147. Mohan A, Oldfield CJ, Radivojac P, *et al.*: **Analysis of molecular recognition features (MoRFs).** *J Mol Biol.* 2006; **362**(5): 1043–1059.
[PubMed Abstract](#) | [Publisher Full Text](#)
148. Vacic V, Oldfield CJ, Mohan A, *et al.*: **Characterization of molecular recognition features, MoRFs, and their binding partners.** *J Proteome Res.* 2007; **6**(6): 2351–2366.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Uversky VN: **Unusual biophysics of intrinsically disordered proteins.** *Biochim Biophys Acta.* 2013; **1834**(5): 932–951.
[PubMed Abstract](#) | [Publisher Full Text](#)
150. Van Herreweghe F, Festjens N, Declercq W, *et al.*: **Tumor necrosis factor-mediated cell death: to break or to burst, that's the question.** *Cell Mol Life Sci.* 2010; **67**(10): 1567–1579.
[PubMed Abstract](#) | [Publisher Full Text](#)
151. Meulmeester E, Jochemsen AG: **p53: A guide to apoptosis.** *Curr Cancer Drug Targets.* 2008; **8**(2): 87–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
152. Zhivotovsky B, Kroemer G: **Apoptosis and genomic instability.** *Nat Rev Mol Cell Biol.* 2004; **5**(9): 752–762.
[PubMed Abstract](#) | [Publisher Full Text](#)
153. Chen H, Ma J, Li W, *et al.*: **A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.** *Mol Cell.* 2007; **27**(5): 717–730.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
154. Sheng Y, Saridakis V, Sarkari F, *et al.*: **Molecular recognition of p53 and MDM2 by USP7/HAUSP.** *Nat Struct Mol Biol.* 2006; **13**(3): 285–291.
[PubMed Abstract](#) | [Publisher Full Text](#)
155. Rustandi RR, Baldisseri DM, Weber DJ: **Structure of the negative regulatory domain of p53 bound to S100B(beta-beta).** *Nat Struct Biol.* 2000; **7**(7): 570–574.
[PubMed Abstract](#) | [Publisher Full Text](#)
156. Mittl PR, Chene P, Grutter MG: **Crystallization and structure solution of p53 (residues 326–356) by molecular replacement using an NMR model as template.** *Acta Crystallogr D Biol Crystallogr.* 1998; **54**(Pt 1): 86–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
157. Kussie PH, Gorina S, Marechal V, *et al.*: **Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.** *Science.* 1996; **274**(5289): 948–953.
[PubMed Abstract](#) | [Publisher Full Text](#)
158. Bochkareva E, Kaustov L, Ayed A, *et al.*: **Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A.** *Proc Natl Acad Sci U S A.* 2005; **102**(43): 15412–15417.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. Feng H, Jenkins LM, Durell SR, *et al.*: **Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.** *Structure.* 2009; **17**(2): 202–210.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Wu HH, Wu PY, Huang KF, *et al.*: **Structural delineation of MDC1-FHA domain binding with CHK2-pThr68.** *Biochemistry.* 2012; **51**(2): 575–577.
[PubMed Abstract](#) | [Publisher Full Text](#)
161. Czabotar PE, Westphal D, Dewson G, *et al.*: **Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis.** *Cell.* 2013; **152**(3): 519–531.
[PubMed Abstract](#) | [Publisher Full Text](#)
162. Peyerl FW, Dai S, Murphy GA, *et al.*: **Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex.** *Cell Death Differ.* 2007; **14**(3): 447–452.
[PubMed Abstract](#) | [Publisher Full Text](#)
163. Czabotar PE, Lee EF, Thompson GV, *et al.*: **Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.** *J Biol Chem.* 2011; **286**(9): 7123–7131.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Current Referee Status:

Referee Responses for Version 1



Oxana Galzitskaya

Institute of Protein Research, Russian Academy of Sciences, Moscow, Russian Federation

Approved: 23 October 2013

Referee Report: 23 October 2013

This paper by Uversky *et al.* describes the proteins involved in programmed cell death pathways (apoptosis, autophagy, and necroptosis). Overall it is an interesting paper deserving of publication and contains very exciting illustrative material.

The authors have performed a study with a particular accent on the intrinsic disordered status of these proteins. To predict the status of disordered residues, the authors used two programs: PONDR FIT and PONDR® VLXT. It should be noted that there are now programs that work with the same or better accuracy of prediction such as [SPINE-D](#), [MFDp](#), [MD](#), [Disopred2](#), [IsUnstruct \(version 2.02\)](#) and [DISOclust](#) (for more details see Table 5 in Lobanov, Sokolovskiy, and Galzitskaya *Journal of Biomolecular Structure & Dynamics* **31(10)**, 1034-1043, 2013). PONDR®VLXT was the least accurate at disorder prediction according to the AUC of 14 programs that were compared in Lobanov *et al.*

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

1 Comment

Author Response

Vladimir Uversky, Department of Molecular Medicine, College of Medicine, University of South Florida, USA

Posted: 28 Oct 2013

First of all, we would like to thank this reviewer for their positive evaluation of our work.

We do agree that the number of available disorder predictors is very large and many of them have accuracies close to that of PONDR FIT. PONDR FIT is a metapredictor representing a consensus of artificial neural network prediction tools, which was developed by combining the outputs of PONDR-VLXT, PONDR-VSL2, PONDR-VL3, FoldIndex, IUPred, and TopIDP. Since PONDR FIT possesses improved prediction accuracy compared to its individual component predictors, and the overall accuracy of this tool is comparable to the accuracies of other meta-predictors, we do not think that the use of additional computational tools is needed for this study.

We also know that PONDR VLXT is not the most accurate disorder predictor. However, this predictor is extremely sensitive to the local peculiarities of amino acid sequences and therefore, is very useful for finding potential disorder-based interaction sites. This point was specifically discussed in our paper dedicated to the development of the related computational tool, alpha-MoRF-PredII (Cheng Y, Oldfield CJ, Meng J, Romero P, Uversky VN, Dunker AK. Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. *Biochemistry*. 2007; **46**(47): 13468-77. PMID: 17973494).

Competing Interests: No competing interests were disclosed.



Martin Vabulas

Institute of Biophysical Chemistry, Goethe University Frankfurt, Frankfurt, Germany

Approved: 26 September 2013

Referee Report: 26 September 2013

By means of several computational tools Uversky *et al.* investigates the level of disorder of key members in the cellular network of apoptosis, autophagy, and necroptosis. The study represents an extension of their previous work (Peng *et al.* 2013) and the two are best read together. I found the study very interesting since it implicates structural disorder as a cell death network building/sustaining principle. Since individual components of the network are analyzed and the results of disorder prediction and connectivity (according to the STRING database) are presented back-to-back the study represents a handy knowledge resource and lays ground for the future experimental validation.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

1 Comment

Author Response

Vladimir Uversky, Department of Molecular Medicine, College of Medicine, University of South Florida, USA

Posted: 28 Oct 2013

We are thankful to Dr. Vabulas for his high evaluation of our work and hope that the readers of F1000Research will find this study useful.

Competing Interests: No competing interests were disclosed.